List of Excipients in Branded Drug KYBELLA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kythera Biopharmaceuticals Inc	KYBELLA	deoxycholic acid	61168-101	BENZYL ALCOHOL
Kythera Biopharmaceuticals Inc	KYBELLA	deoxycholic acid	61168-101	HYDROCHLORIC ACID
Kythera Biopharmaceuticals Inc	KYBELLA	deoxycholic acid	61168-101	SODIUM CHLORIDE
Kythera Biopharmaceuticals Inc	KYBELLA	deoxycholic acid	61168-101	SODIUM HYDROXIDE
Kythera Biopharmaceuticals Inc	KYBELLA	deoxycholic acid	61168-101	SODIUM PHOSPHATE, DIBASIC
Kythera Biopharmaceuticals Inc	KYBELLA	deoxycholic acid	61168-101	WATER

Last updated: September 28, 2026

KYBELLA is a sterile, preservative-containing deoxycholic acid injection whose commercial differentiation depends more on injection tolerability, packaging, dosing workflow, and supply reliability than on a broad excipient platform. The primary opportunity is a lower-pain, lower-volume, ready-to-use presentation that preserves deoxycholic acid solubilization and stability while reducing benzyl alcohol exposure. Generic entry is possible through an abbreviated new drug application, but formulation equivalence, injectable manufacturing, local tolerability, and device-related differentiation create meaningful barriers.

KYBELLA Excipient Strategy, Formulation Patents, and Commercial Opportunities

What is KYBELLA and how does its formulation work?

KYBELLA is an FDA-approved injectable containing deoxycholic acid, a naturally occurring bile acid that disrupts adipocyte membranes after subcutaneous injection. AbbVie markets KYBELLA in the United States for improvement in the appearance of moderate-to-severe convexity or fullness associated with submental fat in adults.[1]

The product is supplied as a sterile, preservative-containing solution for injection:

Attribute	KYBELLA specification
Active ingredient	Deoxycholic acid
Strength	10 mg/mL
Route	Subcutaneous injection
Dosage form	Single-dose vial
Standard vial volume	2 mL
Total active per vial	20 mg
Maximum treatment session	100 mg, or 10 mL
Maximum injection volume per site	0.5 mL
Injection spacing	Approximately 1 cm
Maximum treatment frequency	Once per month
Maximum treatment course	Six treatments
Primary indication	Submental fat in adults
FDA approval	April 2015
FDA applicant at approval	Kythera Biopharmaceuticals
Current commercial owner	AbbVie, following the Allergan acquisition

The product’s mechanism requires direct injection into subcutaneous fat. The formulation therefore has to maintain chemical stability and injectability while limiting tissue irritation across multiple injection sites.

What excipients are in KYBELLA?

KYBELLA contains benzyl alcohol, sodium chloride, water for injection, and pH-adjusting agents. The FDA prescribing information identifies the formulation as a 10 mg/mL deoxycholic acid solution with benzyl alcohol at approximately 4.5 mg/mL and sodium chloride at approximately 8.5 mg/mL. Hydrochloric acid and sodium hydroxide are used to adjust pH.[1]

Excipient or component	Formulation function	Commercial relevance
Benzyl alcohol	Antimicrobial preservative	Supports multidose-use convenience but creates toxicology, tolerability, and market-positioning constraints
Sodium chloride	Tonicity adjustment	Helps control osmolality and injection comfort
Hydrochloric acid	pH adjustment	Controls formulation pH
Sodium hydroxide	pH adjustment	Controls formulation pH
Water for injection	Vehicle	Provides the aqueous injectable medium

The formulation is supplied as a single-dose vial but contains benzyl alcohol. This creates a potentially important product-development question: whether preservative-free packaging could improve tolerability or support pediatric, special-population, or premium aesthetic positioning, even though KYBELLA’s current indication is adults.

Why is benzyl alcohol strategically important?

Benzyl alcohol is the most commercially significant excipient in the KYBELLA formulation. It provides antimicrobial protection, but it also creates several development constraints.

First, local tissue tolerability matters because a treatment session can involve up to 20 injections. The product label reports injection-site reactions, swelling, bruising, pain, numbness, redness, hardness, and itching among the common adverse reactions.[1] A reformulated product that reduces injection discomfort or shortens post-treatment swelling could compete even if it contains the same active ingredient.

Second, benzyl alcohol creates restrictions for certain populations. Benzyl alcohol-containing injectable products require careful consideration in neonates and very young infants because of toxicity concerns. Those populations are not KYBELLA’s approved market, so this issue does not create an immediate indication opportunity. It does, however, influence broader injectable-platform development and preservative-free product design.

Third, benzyl alcohol can affect premium positioning in aesthetic medicine. Providers and patients may value a formulation with fewer excipients, lower preservative exposure, or improved tolerability. Any such claim would require comparative clinical evidence and regulatory support.

What formulation improvements could create commercial opportunities?

The most credible opportunities are incremental improvements rather than a new active-ingredient platform.

Preservative-free single-dose presentation

A preservative-free vial or prefilled syringe could remove benzyl alcohol while maintaining sterility through single-use packaging. Potential benefits include:

• Reduced preservative exposure
• A cleaner excipient profile
• Possible improvement in local tolerability
• Better positioning for patients sensitive to preservatives
• Differentiation from an authorized generic or conventional copy

The main tradeoff is higher packaging and fill-finish cost. A preservative-free product also requires robust container-closure validation and aseptic manufacturing. If supplied in a prefilled syringe, silicone oil, tungsten residues, plunger materials, extractables, and needle compatibility would require evaluation.

Ready-to-use prefilled syringe

KYBELLA is administered through many small-volume injections. A prefilled syringe or cartridge could reduce vial handling, improve dose preparation, and support consistent administration. Commercial benefits could include:

• Lower preparation time in clinics
• Less product waste
• Better control of the delivered dose
• Reduced risk of vial contamination
• Integration with injection guidance systems

The technical challenge is that one treatment session may require multiple syringes or a larger delivery device. A presentation that improves workflow but increases the number of devices may not produce a net benefit.

Lower-volume or higher-concentration formulation

A higher-concentration deoxycholic acid formulation could reduce injection volume. The current maximum treatment session is 10 mL, delivered in 0.5 mL injections. A more concentrated formulation could reduce the number of injections or the volume per site.

This opportunity has substantial risk. Concentration changes can alter:

• Local tissue injury
• Diffusion from the injection site
• Pain and edema
• Deoxycholic acid precipitation
• pH and osmolality
• Injection force
• Dose distribution across subcutaneous fat

A higher-strength formulation would likely require new clinical studies rather than simple bridging.

Low-pain formulation

Pain reduction is a commercially relevant target. Possible approaches include adjustment of pH, osmolality, buffer composition, injection volume, needle gauge, injection rate, or coadministration strategy. Local anesthetics could create a new safety and compatibility profile and may complicate regulatory review.

A formulation that reduces pain without impairing deoxycholic acid activity would have stronger commercial value than an excipient change that only improves laboratory stability.

Device-assisted delivery

A controlled injector, multi-needle applicator, or grid-guided device could improve placement accuracy and treatment consistency. Device development could be paired with:

• A fixed-dose cartridge
• A prefilled delivery system
• Injection-depth control
• Treatment mapping
• Electronic dose tracking

Device patents may provide protection even if the drug formulation is difficult to distinguish from the reference product. The combination would likely be regulated as a combination product if the device is integral to administration.

What formulation patents protect KYBELLA or competing deoxycholic acid products?

KYBELLA’s formulation and method-of-use protection has historically been associated with Kythera and later Allergan. Publicly reported U.S. patent records identify deoxycholic acid formulation and treatment patents related to injectable use, but patent scope and enforceability depend on claim language, prosecution history, terminal disclaimers, maintenance fees, and Orange Book status.

The key patent categories are:

Patent category	Protected subject matter	Commercial impact
Composition patents	Deoxycholic acid injectable formulations and excipient combinations	May restrict formulation copying
Method-of-use patents	Injection of deoxycholic acid for reduction of submental fat	May affect ANDA labeling and skinny-label strategies
Manufacturing patents	Preparation, sterilization, filling, or stability processes	Can create process-development barriers
Device patents	Injection grids, applicators, syringes, or controlled delivery systems	Can protect premium administration models
Packaging patents	Vials, cartridges, and preservative-free presentations	Can support lifecycle management

The commercial question is not whether any patent exists. It is whether an enforceable patent claim covers the proposed generic formulation, its labeled use, or its manufacturing process at the intended launch date.

What is the Orange Book status of KYBELLA?

KYBELLA is a small-molecule injectable drug, so FDA Orange Book listings and 505(b)(2) or ANDA pathways are relevant. It is not a biologic and does not receive biosimilar protection under the Public Health Service Act.

A prospective generic applicant would generally evaluate:

1. Listed patents for KYBELLA in the Orange Book.
2. Pediatric exclusivity, if any.
3. New chemical entity or other regulatory exclusivity periods.
4. Patent expiration and any patent-term adjustment.
5. Paragraph IV certification exposure.
6. Whether the proposed label omits patented uses.
7. Whether differences in formulation require a 505(b)(2) application instead of an ANDA.

The product’s original five-year new chemical entity exclusivity would have expired in 2020, assuming no qualifying delay or extension altered the period. Current competitive barriers are therefore more likely to arise from listed patents, formulation equivalence, manufacturing capability, and commercial economics than from remaining NCE exclusivity.[2]

When does KYBELLA lose exclusivity and when could generic entry occur?

Generic entry timing depends on the latest enforceable patent and the outcome of any Paragraph IV litigation. FDA approval does not guarantee immediate launch because an ANDA applicant can face a 30-month stay after timely patent litigation by the reference-product sponsor.[2]

Paragraph IV challenge risks

A Paragraph IV applicant could argue that listed patents are invalid, unenforceable, or not infringed. The reference sponsor could respond with patent litigation. The principal technical arguments could involve:

• Whether the proposed excipient concentrations fall within the claims
• Whether the applicant’s formulation has the claimed pH or osmolality
• Whether the proposed label induces infringement of a patented method
• Whether the patent claims are obvious in view of prior bile-acid injection literature
• Whether the reference formulation has adequate written description or enablement

A generic applicant could also use a section viii statement to omit a patented method of use if the product label can be designed without the protected indication. That strategy may be difficult for KYBELLA because the approved product has a focused indication and the commercial value is concentrated in submental-fat treatment.

How strong is the KYBELLA patent estate?

The estate is strategically meaningful but technically vulnerable to design-around activity. Deoxycholic acid is an established endogenous bile acid, so composition-of-matter protection for the active ingredient is weaker than for a novel chemical entity. The more defensible protection is likely to focus on:

• Specific injectable formulations
• Concentration and pH ranges
• Treatment protocols
• Injection patterns
• Combination of formulation and indication
• Delivery systems

Patent strength can be assessed across five dimensions:

Factor	KYBELLA assessment
Active-ingredient novelty	Limited, because deoxycholic acid is known
Formulation differentiation	Moderate, depending on claim breadth and prior art
Method-of-use value	High commercial relevance because the indication is focused
Manufacturing barriers	Moderate to high for sterile injectable production
Device and workflow protection	Potentially strong for differentiated administration systems

The strongest lifecycle strategy would combine a reformulated product with a device and a validated tolerability or workflow benefit. A stand-alone excipient substitution is easier for competitors to design around.

Is biosimilar risk relevant to KYBELLA?

No. KYBELLA is a chemically synthesized or chemically defined small-molecule injectable, not a biological product. Biosimilar approval under the biologics pathway is therefore not the relevant competitive route.

The relevant alternatives are:

• ANDA-based generic deoxycholic acid injection
• 505(b)(2) reformulations
• Compounded preparations, subject to applicable federal and state requirements
• Device-enabled aesthetic treatments
• Liposuction and surgical submental-fat reduction
• Cryolipolysis and other noninjectable procedures

A 505(b)(2) product could pursue a different concentration, presentation, excipient profile, or administration device while relying in part on FDA’s findings for KYBELLA.

Which companies and products compete with KYBELLA?

KYBELLA competes in a procedure-driven aesthetic market rather than a conventional chronic-prescription market.

Competitive category	Examples	Relevance
Injectable deoxycholic acid	KYBELLA and potential generic or 505(b)(2) products	Direct pharmaceutical competition
Cryolipolysis	CoolSculpting and similar systems	Noninjectable alternative for fat reduction
Energy-based devices	Radiofrequency, ultrasound, and laser systems	Compete for provider and patient budgets
Surgical treatment	Submental liposuction and neck contouring	Higher intensity, potentially more immediate results
Topical or oral products	Various cosmetic products	Limited mechanistic comparability

The main commercial advantage of a competing injectable would be a lower total treatment cost, reduced injection pain, faster recovery, fewer treatment visits, or improved provider economics.

What geographic opportunities exist for KYBELLA-type excipients?

Geographic strategy should distinguish regulatory approval from commercial demand.

The United States has the most established regulatory and commercial position for KYBELLA. Europe and other markets may use different brand names, indications, or regulatory classifications for deoxycholic acid products. Excipient acceptability can vary by jurisdiction, especially for preservative-containing injectables and novel delivery systems.

Potential regional strategies include:

• Preservative-free presentations for markets with stricter excipient preferences
• Vial sizes tailored to local treatment protocols
• Multi-dose formats where permitted and commercially justified
• Lower-cost formulations for price-sensitive markets
• Premium prefilled devices for high-volume aesthetic clinics

A global product cannot assume that an excipient concentration accepted in the United States will receive identical treatment elsewhere. Regional requirements for benzyl alcohol, container systems, extractables, sterility, and in-use stability must be assessed independently.

What manufacturing and intellectual-property barriers affect entry?

Sterile injectable manufacturing is a major barrier to commercial entry. A prospective competitor needs validated control of:

• Raw-material quality for deoxycholic acid
• Solution preparation and pH adjustment
• Bioburden and endotoxin control
• Sterile filtration or aseptic processing
• Container-closure integrity
• Particulate control
• Fill-volume accuracy
• Stability over the proposed shelf life
• Visual inspection and release testing

The product’s apparent formulation simplicity does not eliminate development risk. Deoxycholic acid can create challenges in solubility, surface interactions, pH control, and local tissue tolerability. A formulation that matches the label qualitatively may still fail comparative physicochemical or clinical expectations.

What is the revenue exposure and commercial opportunity?

KYBELLA revenue is exposed to competition from lower-cost injectables and procedure-based substitutes. The product is administered in aesthetic practices, where reimbursement is limited and patient out-of-pocket spending drives demand.

Commercial opportunity is strongest in four models:

1. A lower-cost generic that captures price-sensitive patients and clinics.
2. A premium formulation that reduces pain, swelling, or treatment time.
3. A prefilled or device-enabled product that improves provider throughput.
4. A regional product with a lower-cost vial configuration or simplified supply chain.

The strongest premium opportunity is likely a complete treatment system rather than an excipient-only substitute. A formulation, delivery device, treatment grid, and clinical workflow package can create switching costs and support differentiated pricing.

How does KYBELLA compare with a preservative-free competitor?

Attribute	Current KYBELLA-type product	Preservative-free competitor
Benzyl alcohol	Present	Absent or materially reduced
Packaging	Single-dose vial	Single-dose vial, prefilled syringe, or cartridge
Formulation risk	Established	Requires new stability and compatibility work
Manufacturing cost	Lower with conventional vial filling	Potentially higher
Tolerability positioning	Existing clinical profile	Opportunity for comparative benefit
Regulatory pathway	Reference product or ANDA	ANDA if equivalent, otherwise possible 505(b)(2)
IP opportunity	Existing formulation and method claims	New formulation, device, and packaging claims
Commercial differentiation	Brand recognition and clinical history	Workflow, tolerability, and convenience

Key Takeaways

• KYBELLA contains 10 mg/mL deoxycholic acid in an aqueous injectable formulation with benzyl alcohol, sodium chloride, water for injection, and pH-adjusting agents.
• Benzyl alcohol is the principal excipient opportunity because a preservative-free presentation could support tolerability and premium positioning.
• The most valuable lifecycle products would combine formulation changes with prefilled delivery, controlled injection, or improved treatment workflow.
• KYBELLA is not subject to biosimilar competition. Generic and 505(b)(2) pathways are the relevant routes.
• Paragraph IV litigation could focus on formulation ranges, method-of-use claims, labeling, and design-around strategies.
• Sterile manufacturing, local tissue tolerability, and comparative injectability are substantial barriers to entry.
• A simple excipient substitution is less defensible than a formulation-device-treatment system protected by coordinated patent filings.
• Geographic opportunities depend on local acceptance of benzyl alcohol, injectable packaging, preservative levels, and aesthetic treatment economics.

FAQs About KYBELLA Excipients and Commercial Competition

Does KYBELLA contain benzyl alcohol?

Yes. The FDA label identifies benzyl alcohol at approximately 4.5 mg/mL as an inactive ingredient and preservative.[1]

Can a generic KYBELLA remove benzyl alcohol?

Not through a conventional ANDA unless the proposed product remains pharmaceutically equivalent and meets applicable FDA requirements. Removing benzyl alcohol may require a different regulatory pathway if the formulation is not equivalent to the reference product.

Is deoxycholic acid protected by a composition-of-matter patent?

The active ingredient is a known bile acid. Commercial protection is more likely to depend on injectable formulation, treatment method, packaging, device, and manufacturing claims than on broad protection for deoxycholic acid itself.

Could a prefilled syringe replace the KYBELLA vial?

Potentially, but the product would require assessment of syringe compatibility, dose accuracy, injection force, stability, extractables, container closure, and whether a single syringe can support the multi-injection treatment protocol.

What is the most attractive excipient opportunity for a KYBELLA competitor?

A preservative-free, low-pain formulation with a ready-to-use delivery system offers the clearest combination of clinical, workflow, and commercial differentiation.

References

1. U.S. Food and Drug Administration. (2024). KYBELLA (deoxycholic acid) injection, prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certification requirements. FDA.

4. AbbVie Inc. (2024). Annual report. AbbVie.

5. U.S. Food and Drug Administration. (2015). FDA approves treatment to reduce fat below the chin. FDA.